Using a healthcare discovery platform that combines biology, mass spectrometry, and machine learning, Tegmine Therapeutics aims to create sustainable cancer and tumor therapies by targeting glycoproteins, which are a hallmark of numerous solid cancers and drive aggressive disease. Their proprietary TegMiner™ platform enables the discovery of unique cancer epitopes, allowing the development of next-generation antibody-drug that are more specific to the tumor, sparing normal healthy tissues. The result is revolutionary new antibody-based therapies for cancer that dramatically increase efficacy while reducing toxic side effects, providing patients with unmet needs with life-changing treatment options.